Targets for the treatment of erectile dysfunction: Is NO/cGMP still the answer?

Recent Patents on Cardiovascular Drug Discovery

Volumn 2, Issue 2, 2007, Pages 119-132

  Leite, Romulo ^a   Giachini, Fernanda R C ^a,b   Carneiro, Fernando S ^a,b   Nunes, Kênia P ^a,c   Tostes, Rita C ^a,b   Webb, Robert C ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

cGMP; Erectile dysfunction; Gene therapy; Growth factors; Ion channels; Nitric oxide; Nitric oxide synthase; PDE 5 inhibitors; Penile erection; RhoA Rho kinase

Indexed keywords

1 (2 HYDROXY 5 TRIFLUOROMETHYLPHENYL) 5 TRIFLUOROMETHYL 2(3H) BENZIMIDAZOLONE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; ADENOVIRUS VECTOR; ALPHA TOCOPHEROL; APOMORPHINE; ASCORBIC ACID; CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GPI 1485; INDUCIBLE NITRIC OXIDE SYNTHASE; N ACETYLNORLEUCYLASPARTYLHISTIDYL DEXTRO PHENYLALANYLARGINYLTRYPTOPHYLLYSINE 2,7 CYCLIC AMIDE; NEURONAL NITRIC OXIDE SYNTHASE; NEUROTROPHIN 3; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PAPAVERINE; PHENTOLAMINE; PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN E1; SELENATE; SILDENAFIL; SILDENAFIL NITRATE; SOMATOMEDIN C; SUPEROXIDE DISMUTASE; TACROLIMUS; TADALAFIL; TETRAHYDROBIOPTERIN; UNINDEXED DRUG; VARDENAFIL;

ADJUVANT THERAPY; ANTIOXIDANT ACTIVITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SELECTIVITY; DRUG TARGETING; DYSPEPSIA; ERECTILE DYSFUNCTION; EXERCISE; FLUSHING; GENE TRANSFER; GENETIC TRANSFECTION; HUMAN; MALE; NEUROPHYSIOLOGY; NONHUMAN; NONVIRAL GENE THERAPY; PATENT; PATHOGENESIS; PENIS ERECTION; PENIS PROSTHESIS; PRIORITY JOURNAL; REVIEW; RHINITIS; RISK FACTOR; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SMOOTH MUSCLE RELAXATION; THERAPY RESISTANCE; VIRAL GENE THERAPY; VISUAL DISORDER;

CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; ERECTILE DYSFUNCTION; HUMANS; MALE; NITRIC OXIDE;

EID: 34250741398     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489007780832579     Document Type: Review

References (164)

1. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993; 270(1): 83-90.
2. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151(1): 54-61.
3. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999; 84(1): 50-56.
4. Jonler M, Moon T, Brannan W, Stone NN, Heisey D, Bruskewitz RC. The effect of age, ethnicity and geographical location on impotence and quality of life. Br J Urol 1995; 75(5): 651-55.
5. Muller A, Mulhall JP. Cardiovascular disease, metabolic syndrome and erectile dysfunction. Curr Opin Urol 2006; 16(6): 435-43.
6. Lewis RW, Lue TF, Basson R, et al. Definitions, classification, and epidemiology of sexual dysfunction. Sexual Medicine: Sexual Dysfunction in Men and Women. Health Publication 2004; 39-72.
7. Lue TF. Erectile dysfunction. N Engl J Med 2000; 342(24): 1802-1813.
8. Privieiro FR, Webb RC, Teixeira CE. Neurophysiological basis of penile erection. Acta Pharma Sinica 2007.
9. Anderson KE. Pharmacology of penile erection. Pharmacol Rev 2001; 53(3): 417-50.
10. Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev 1995; 75(1): 191-236.
11. Argiolas A, Melis MR. Central control of penile erection: role of the paraventricular nucleus of the hypothalamus. Prog Neurobiol 2005; 76(1): 1-21.
12. Argiolas A, Melis MR. The neurophysiology of the sexual cycle. J Endocrinol Invest 2003; 26(3 Suppl): 20-22.
13. Guiliano F, Rampin O. Neural control of erection. Physiol Behav 2004; 83(2): 189-201.
14. Rampin O. Neural control of erection. J Soc Biol 2004; 198(3): 217-230.
15. Argiolas A, Melis MR. The role of oxytocin and the paraventricular nucleus in the sexual behaviour of male mammals. Physiol Behav 2004; 83(2): 309-317.
16. Lundberg JM. Pharmacology of cotransmission in the autonomic nervous system: integrative aspects on amines, neuropeptides, adenosine triphosphate, amino acids and nitric oxide. Pharmacol Rev 1996; 48(1): 113-178.
17. Furchgott RF, Vanhoutte PM, Vasodilatation: vascular smooth muscle, peptides, autonomic nerve and endothelium 1988; New York. 401-414.
18. Ignarro LJ, Bush PA, Buga GM, Wood KS, Fukuto JM, Rajfer J. Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun 1990; 170(2): 843-50.
19. Burnett AL. Nitric oxide in the penis: physiology and pathology. J Urol 1997; 157(1): 320-24.
20. Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992; 326(2): 90-94.
21. Hofmann F, Feil R, Kleppisch T, Schlossmann J. Function of cGMP-dependent protein kinases as revealed by gene deletion. Physiol Rev 2006; 86(1): 1-23.
22. 2+ sensitization of contraction in vascular smooth muscle. J Biol Chem 2000; 275(28): 21722-21729.
23. Linder AE, Webb RC, Mills TM, Ying Z, Lewis RW, Teixeira CE. Rho-kinase and RGS-containing RhoGEFs as molecular targets for the treatment of erectile dysfunction. Curr Pharm Des 2005; 11(31): 4029-4040.
24. Jeremy JY, Morgan RJ, Mikhailidis DP, Dandona P. Prostacyclin synthesis by the corpora cavernosa of the human penis: evidence for muscarinic control and pathological implications. Prostaglandins Leukot Med 1986; 23(2-3): 211-216.
25. Jeremy JY, Mikhailidis DP, Dandona, P. Muscarinic stimulation of prostacyclin synthesis by the rat penis. Eur J Pharmacol 1986; 123(1): 67-71.
26. Saenz de Tejada I. Molecular mechanisms for the ragulation of penile smooth muscle contractility. Int J Impot Res 2002; 14 Suppl 1: S6-10.
27. Francis SH, Turko IV, Corbin JD. Cyclic nucleotide phosphodiestrases: relating structure and function. Prog Nucleic Acid Res Mol Biol 2001; 65: 1-52.
28. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, Osterloh IH, Gingell C. Sildenafil: an orally active type 5 cyclic GMP-specific phophodiesterase inhibitor for the treatment of penile erectile dyfunction. Int J Impot Res 1996; 8(2): 47-52.
29. Turko IV, Ballard SA, Francis SH, Corbin JD. Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds. Mol Pharmacol 1999; 56(1): 124-30.
30. Burnett AL, Tillman SL, Chang TS, Epstein JI, Lowenstein CJ, Bredt DS, Snyder SH, Walsh PC. Immunohistochemical localization of nitric oxide synthase in the autonomic innervation of the human penis. J Urol 1993; 150(1): 73-76.
31. Alm P, Larsson B, Ekblad E, Sundler F, Andersson KE. Immunohistochemical localization of peripheral nitric oxide synthase-containing nerves using antibodies raised against synthesized C- and N-terminal fragments of a cloned enzyme from rat brain. Acta Physiol Scand 1993; 148(4): 421-429.
32. Dail WG, Barba V, Leyba L, Galindo R. Neural and endothelial nitric oxide synthase activity in rat penile arectile tissue. Cell Tissue Res 1995; 282(1): 109-116.
33. Stanarius, A, Uckert S, Machtens SA, Stief CG, Wolf G, Jonas U. Immunocytochemical distribution of nitric oxide synthase in the human corpus cavemosum: an electron microscopical study using the tyramide signal amplification technique. Urol Res 2001; 29(3): 168-172.
34. Burnett AL, Nelson RJ, Calvin DC, et al. Nitric oxide-dependent penile erection in mice lacking neuronal nitric oxide synthase. Mol Med 1996; 2(3): 288-296.
35. Burnett AL, Chang AG, Crone JK, Huang PL, Sezen SE. Noncholinergic penile erection in mice lacking the gene for endothelial nitric oxide synthase. J Androl 2002; 23(1): 92-97.
36. Hilgers RH, Webb RC. Molecular aspects of arterial smooth muscle contraction: focus on Rho. Exp Biol Med (Maywood) 2005; 230(11): 829-835.
37. 2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev 2003; 83(4): 1325-1358.
38. Noda M, Yasuda-Fukazawa C, Moriishi K, et al. Involvement of rho in GTP gamma S-induced enhancement of phosphorylation of 20 kDa myosin light chain in vascular smooth muscle cells: inhibition of phosphatase activity. FEBS Lett 1995; 367(3): 246-250.
39. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature 2002; 420(6916): 629-635.
40. Schmidt A, Hall A. Guanine nucleotide exchange factors for Rho GTPases: turning on the switch. Genes Dev 2002; 16(13): 1587-1609.
41. Chitaley K, Webb RC. Nitric oxide induces dilation of rat aorta via inhibition of rho-kinase signaling. Hypertension 2002; 39(2 Pt 2): 438-442.
42. Musicki B, Burnett AL. eNOS function and dysfunction in the penis. Exp Biol Med (Maywood) 2006; 231(2): 154-65.
43. Cellek S, Moncada S. Nitrergic control of peripheral sympathetic responses in the human corpus cavernosum: a comparison with other species. Proc Natl Acad Sci U S A 1997; 94(15): 8226-8231.
44. Ferrini MG, Davila HH, Valente EG, Gonzalez-Cadavid NF, Rajfer J. Aging-related induction of inducible nitric oxide synthase is vasculo-protective to the arterial media. Cardiovasc Res 2004; 61(4): 796-805.
45. Sommer F, Klotz T, Steinritz D, Bloch W. Evaluation of tetrahydrobiopterin (BH4) as a potential therapeutic agent to treat erectile dysfunction. Asian J Androl 2006; 8(2): 159-167.
46. Jones RW, Rees RW, Minhas S, Ralph D, Persad RA, Jeremy JY. Oxygen free radicals and the penis. Expert Opin Pharmacother 2002; 3(7): 889-897.
47. Agarwal A, Nandipati KC, Sharma RK, Zippe CD, Raina R. Role of oxidative stress in the pathophysiological mechanism of erectile dysfunction. J Androl 2006; 27(3): 335-347.
48. Gocmen C, Secilmis A, Kumcu EK, et al. Effects of vitamin E and sodium selenate on neurogenic and endothelial relaxation of corpus cavernosum in the diabetic mouse. Eur J Pharmacol 2000; 398(1): 93-98.
49. Gur S, Karahan ST, Ozturk B, Badilli M. Effect of ascorbic acid treatment on endothelium-dependent and neurogenic relaxation of corpus cavernosum from middle-aged non-insulin dependent diabetic rats. Int J Urol 2005; 12(9): 821-828.
50. Esposito K, Ciotola M, Giugliano, F, et al. Mediterranean diet improves erectile function in subjects with the metabolic syndrome. Int J Impot Res 2006; 18(4): 405-410.
51. Kendirci M, Teloken PE, Champion HC, Hellstrom WJ, Bivalacqua TJ. Gene therapy for erectile dysfunction: fact or fiction? Eur Urol 2006; 50(6): 1208-1222.
52. Lau DH, Kommu SS, Siddiqui EJ, et al. Gene therapy and erectile dysfunction: the current status. Asian J Androl 2007; 9(1): 8-15.
53. Henriques ST, Melo MN, Castanho MA. Cell-penetrating peptides and antimicrobial peptides: how different are they? Biochem J 2006; 399(1): 1-7.
54. Kendirci M, Gur S, Sikka SC. Gene therapy for erectile dysfunction. Front Biosci 2005; 10: 2758-2769.
55. Bivalacqua TJ, Musicki B, Usta MF, et al. Endothelial nitric oxide synthase gene therapy for erectile dysfunction. Curr Pharm Des 2005; 11(31): 4059-4067.
56. Bivalacqua TJ, Champion HC, Mehta YS, et al. Adenoviral gene transfer of endothelial nitric oxide synthase (eNOS) to the penis improves age-related erectile dysfunction in the rat. Int J Impot Res 2000; 12 Suppl 3: S8-17.
57. Champion HC, Bivalacqua TJ, D'Souza FM, et al. Gene transfer of endothelial nitric oxide synthase to the lung of the mouse in vivo. Effect on agonist-induced and flow-mediated vascular responses. Circ Res 1999; 84(12): 1422-1432.
58. Bivalacqua TJ, Usta MF, Champion HC, et al. Gene transfer of endothelial nitric oxide synthase partially restores nitric oxide synthesis and erectile function in streptozotocin diabetic rats. J Urol 2003; 169(5): 1911-1917.
59. Magee TR, Ferrini M, Garban HJ, et al. Gene therapy of erectile dysfunction in the rat with penile neuronal nitric oxide synthase. Biol Reprod 2002; 67(1): 20-28.
60. Tirney S, Mattes CE, Yoshimura N, et al. Nitric oxide synthase gene therapy for erectile dysfunction: comparison of plasmid, adenovirus, and adenovirus-transduced myoblast vectors. Mol Urol 2001; 5(1): 37-43.
61. Garban H, Marquez D, Magee T, et al. Cloning of rat and human inducible penile nitric oxide synthase. Application for gene therapy of erectile dysfunction. Biol Reprod 1997; 56(4): 954-63.
62. Erkan E, Muslumanoglu AY, Oktar T, Sanli O, Ozbek U, Kadioglu A. Polymorphism of endothelial nitric oxide synthase gene in patients with erectile dysfunction. J Sex Med 2006; 3(1): 69-75.
63. - and improves erectile funtion in aged rats. Am J Physiol Heart Circ Physiol 2003; 284(4): H1408-1421.
64. Bivalacqua TJ, Usta MF, Kendirci M, et al. Superoxide anion production in the rat penis impairs erectile function in diabetes: influence of in vivo extracellular superoxide dismutase gene therapy. J Sex Med 2005; 2(2): 187-97; discussion 197-198.
65. Geliebter, J., Melman, A., Christ, G.J., Rehman, J.: US20006150338 ( 2000).
66. Kernohan AP, McIntyre M, Hughes DM, Tam SW, Worcel M, Reid JL. An oral yuhimbine/L-arginine combination (NMI 861) for the treatment of male erectile dysfunction: a pharmacokinetic, pharmacodynamic and interaction study with intravenous nitroglycerine in healthy male subjects. Br J Clin Pharmacol 2005; 59(1): 85-93.
67. Lebret T, Herve JM, Gorny P, Worcel M, Botto H. Efficacy and safety of a novel combination of L-arginine glutamate and yohimbine hydrochloride: a new oral therapy for erectile dysfunction. Eur Urol 2002; 41(6): 608-613.
68. Lin G, Hayashi N, Carrion R, Chang LJ, Lue, TF, Lin CS. Improving erectile function by silencing phosphodiesterase-5. J Urol 2005; 174(3): 1142-1148.
69. Badwan, A.: US20067084144 (2006).
70. Orme, M.W., Schultze, L. M., Sawyer, J. S., Daugan, A. C-L., Brown, R.: US20056962918 (2005).
71. Campbell, S.F., Mackenzie A.R., Wood, A.: US20036656945 (2003).
72. Campbell, S.F., Mackenzie, A.R., Wood, A.: US20016300335 (2001).
73. Doherty, J.P.C., Place, V. A., Smith, W. L.: US20036548490 (2003).
74. Shukla N, Jones R, Persad R, Angelini GD, Jeremy JY. Effect of sildenafil citrate and a nitric oxide donating sildenafil derivative, NCX 911, on cavernosal relaxation and superoxide formation an hypercholesterolaemic rabbits. Eur J Pharmacol 2005, 517(3): 224-231.
75. Kalsi JS, Ralph DJ, Thomas P, Bellringer J, Minhas S, Kell PD, Cellek S. A nitric oxide-releasing PDE5 inhibitor relaxes human corpus cavernosum in the absence of endogenous nitric oxide. J Sex Med 2005; 2(1): 53-57.
76. Baracat JS, Teixeira CE, Okuyama CE, et al. Relaxing effects induced by the soluble guanylyl cyclase stimulator BAY 41-2272 in human and rabbit corpus cavernosum. Eur J Pharmacol 2003; 477(2): 163-169.
77. Bischoff E, Schramm M, Straub A, Feurer A, Stasch JP. BAY 41-2272: a stimulator of soluble guanylyl cyclase induces nitric oxide-dependent penile erection in vivo. Urology 2003; 61(2): 464-467.
78. Yeager, J.L., Buyuktimkin, N., Buyuktimkin, S.: US20046693135 (2004).
79. Yeager, J.L., Buyuktimkin, N., Buyuktimkin, S.: US20066693135 (2006).
80. Adams, M.A., Heaton, J.P.W., Maurice, D.H.: US20046747063 (2004).
81. Kanakaris, P., Karouzakis P.: US20036589990 (2003).
82. Mills TM, Lewis RW, Wingard CJ, Chitaley K, Webb RC. Inhibition of ionic contraction - a novel way to approach erectile dysfunction. J Androl 2002; 23(5): S5-9.
83. Ishizaki T, Uehata M, Tamechika I, et al. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol 2000; 57(5): 976-983.
84. Narumiya S, Ishizaki T, Uehata M. Use and properties of ROCK-specific inhibitor Y-27632. Methods Enzymol 2000; 325: 273-84.
85. Chitaley K, Wingard CJ, Clinton Webb R, et al. Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway. Nat Med 2001; 7(1): 119-22.
86. Mills TM, Chitaley K, Wingard CJ, Lewis RW, Webb RC. Efect of Rho-kinase inhibition on vasoconstriction in the penile circulation. J Appl Physiol 2001; 91(3): 1269-1273.
87. Mills TM, Pollock DM, Lewis RW, Branam HS, Wingard CJ. Endothelin-1-induced vasoconstriction is inhibited during erection an rats. Am J Physiol Regul Integr Comp Physiol 2001; 281(2): R476-483.
88. Mills TM, Chitaley K, Lewis RW. Vasoconstrictors in erectile physiology. Int J Impot Res 2001; 13 Suppl 5: S29-34.
89. Rees RW, Ralph DJ, Royle M, Moncada S, Cellek S. Y-27632, an inhibitor of Rho-kinase, antagonizes noradrenergic contractions in the rabbit and human penile corpus cavernosum. Br J Pharmacol 2001; 133(4): 455-458.
90. 2+ sensitivity regulates contractility of rabbit corpus cavernosum smooth muscle. J Urol 2003; 169(6): 2412-2416.
91. Sasaki Y, Suzuki M, Hidaka H. The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway. Pharmacol Ther 2002; 93(2-3): 225-232.
92. Teixeira CE, Ying Z, Webb RC. Proerectile effects of the Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinolinyl)sulfonyl] homopiperazine (H-1152) in the rat penis. J Pharmacol Exp Ther 2005; 315(1): 155-162.
93. Chitaley K, Bivalacqua TJ, Champion HC, et al. Adeno-associated viral gene transfer of dominant negative RhoA enhances erectile function in rats. Biochem Biophys Res Commun 2002; 298(3): 427-432.
94. 2+ sensitization in erectile function. J Biol Chem 2002; 277(34): 30614-30621.
95. Seftel A. Adeno-associated viral gene transfer of dominant negative RhoA enhances erectile function in rats. J Urol 2003; 170(2 Pt 1): 682.
96. Bolz SS, Vogel L, Sollinger D, Derwand R, de Wit C, Loirand G, Pohl U. Nitric oxide-induced decrease in calcium sensitivity of resistance arteries is attributable to activation of the myosin light chain phosphatase and antagonized by the RhoA/Rho kinase pathway. Circulation 2003; 107(24): 3081-3087.
97. Kimura K, Ito M, Amano M, et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 1996; 273(5272): 245-248.
98. Surks HK, Mochizuki N, Kasai Y, et al. Regulation of myosin phosphatase by a specific interaction with cGMP- dependent protein kinase 1alpha. Science 1999; 286(5444): 1583-1587.
99. Mills TM, Chitaley K, Lewis RW, Webb RC. Nitric oxide inhibits RhoA/ Rho-kinase signaling to cause penile erection. Eur J Pharmacol 2002; 439(1-3): 173-174.
100. Ming XF, Viswambharan H, Barandier C, et al. Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol Cell Biol 2002; 22(24): 8467-8477.
101. Bivalacqua TJ, Champion HC, Usta MF, Cellek S, Chitaley K, Webb RC, Lewis RL, Mills TM, Hellstrom WJ, Kadowitz PJ. RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. Proc Natl Acad Sci USA 2004; 101(24):9121-9126.
102. Mills TM, Stopper VS, Reilly CM. Sites of androgenic regulation of cavernosal blood pressure during penile erection in the rat. Int J Impot Res 1996; 8(1): 29-34.
103. Mills TM, Lewis RW. The Role of Andorgens in the Erectile Response: A 1999 Perspective. Mol Urol 1999; 3(2): 75-86.
104. Wingard CJ, Johnson JA, Holmes A, Prikosh A. Improved erectile function after Rho-kinase inhibition in a rat castrate model of erectile dysfunction. Am J Physiol Regul Integir Comp Physiol 2003; 284(6): R1572-1579.
105. Chitaley K, Webb RC, Dorrance AM, Mills TM. Decreased penile erection in DOCA-salt and stroke prone-sponteneously hypertensive rats. Int J Impot Res 2001; 13 Suppl 5: S16-20.
106. Wilkes N, White S, Stein P, Bernie J, Rajasekaran M. Phosphodiesterase-5 inhibition synergizes rho-kinase antagonism and enhances erectile response in male hypertensive rats. Int J Impot Res 2004; 16(2): 187-194.
107. Jin L, Liu T, Lagoda GA, Champion HC, Bivalacqua TJ, Burnett AL. Elevated RhoA/Rho-kinase activity in the aged rat penis: mechanism for age-associated erectile dysfunction. FASEB J 2006; 20(3): 536-538.
108. Nakamura Y, Kaneto H, Miyatsuka T, et al. Marked increase of insulin gene transcription by suppression of the Rho/Rho-kinase pathway. Biochem Biophys Res Commun 2006; 350(1): 68-73.
109. Pu XY, Hu LQ, Wang HP, Luo YX, Wang XH. Improvement in erectile dysfunction after insulin-like growth factor-1 gene therapy in diabetic rats. Asian J Androl 2007; 9(1): 83-91.
110. Doe C, Bentley R, Behm DJ, et al. Novel Rho kinse inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther 2007; 320(1): 89-98.
111. Ying Z, Jin L, Dorrance AM, Webb RC. Increaseed expression of mRNA for regulator of G protein signaling domain-containing Rho guanine nucleotide exchange factors in aorta from stroke-prone spontaneously hypertensive rats. Am J Hypertens 2004; 17(10): 981-985.
112. Spektor M, Rodriguez R, Rosenbaum RS, Wang HZ, Melman A, Christ GJ. Potassium channels and human corporeal smooth muscle cell tone: further evidence of the physiological relevance of the Maxi-K channel subtype to the regulation of human corporeal smooth muscle tone in vitro. J Urol 2002; 167(6): 2628-2635.
113. Werner ME, Zvara P, Meredith AL, Aldrich RW, Nelson MT. Erectile dysfunction in mice lacking the large-conductance calcium-activated potassium (BK) channel. J Physiol 2005; 567(Pt 2): 545-556.
114. Christ GJ. K channels as molecular targets for the treatment of erectile dysfunction. J Androl 2002; 23(5): S10-19.
115. Lee SW, Wang HZ, Christ GJ. Characterization of ATP-sensitive potassium channels in human corporal smooth muscle cells. Int J Impot Res 1999; 11(4): 179-88.
116. Venkateswarlu K, Giraldi A, Zhao W, et al. Potassium channels and human corporeal smooth muscle cell tone: diabetes and relaxation of human corpus cavernosum smooth muscle by adenosine triphosphate sensitive potassium channel openers. J Urol 2002; 168(1): 355-61.
117. Christ GJ, Wang HZ, Venkateswarlu K, Zhao W, Day NS. Ion Channels and Gap Junctions: Their Role in Erectile Physiology, Dysfunction, and Future Therapy. Mol Urol 1999; 3(2): 61-73.
118. Christ GJ,Brink PR. Analysis of the presence and physiological relevance of subconducting states of Connexin43-derived gap junction channels in cultured human corporal vascular smooth muscle cells. Circ Res 1999; 84(7): 797-803.
119. Melman A, Bar-Chama N, McCullough A, Davies K, Christ G. The first human trial for gene transfer therapy for the treatment of erectile dysfunction: preliminary results. Eur Urol 2003; 48(2): 314-318.
120. Schiff JD, Melman A. Ion channel gene therapy for smooth muscle disorders: relaxing smooth muscles to treat erectile dysfunction. Assay Drug Dev Technol 2006; 4(1): 89-95.
121. Christ, G.J., Melman, A.: US20016271211 (2001).
122. Gelibter, J., Melman, A., Christ, G. J., Rehman, J.: US20006150338 ( 2000).
123. Briganti A, Chun FK, Salonia A, Zanni G, Deho F, Barbieri L, Kerakiewicz PI, Rigatti P, Montorsi F. A comparative review of apomorphine formulations for erectile dysfunction: recommendations for use in the elderly. Drugs Aging 2006; 23(4): 309-319.
124. Brioni JD, Moreland RB, Cowart M, et al. Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats. Proc Natl Acad Sci U S A 2004; 101(17): 6758-6763.
125. Kolasa T, Matulenko MA, Hakeem AA, et al. 1-aryl-3-(4-pyridine-2-ylpiperazin-1-yl)propan-1-one oximes as potent dopamine D4 receptor agonists for the treatment of erectile dysfunction. J Med Chem 2006; 49(17): 5093-6109.
126. Enguehard-Gueiffier C, Hubner H, El Hakmaoui A, et al. 2-[(4-phenyl-piperazin-1-yl)methyl]imidazo(di)azines as selective D4-ligands. Induction of penile erection by 2-[4-(2-methoxyphenyl)piperazin-1-ylmethyl]imidazo [1,2-a]pyridine (PIP3EA), a potent and selective D4 partial agonist. J Med Chem 2006; 49(13): 3938-3947.
127. Cowart, M.B., Pramila, A.B., Daanen, J.F., Stewart, A.O., Patel, M. V., Kolasa, T., Brioni, J.D., Rohde, J., Engstrom, K.M.: US20056960389 ( 2005).
128. Cowart, M.B., Pramila, A.B., Daanen, J.F., Stewart, A.O., Patel, M.V., Kolasa, T., Brioni, J.D., Rohde, J.: US20067022728 (2006).
129. Giuliano F. Control of penile erection by the melanocortinergic system: experimental evidences and therapeutic perspectives. J Androl 2004; 25(5): 683-91.
130. Basu, A.G.T.C., Girten., B. E., Griffith, M. C., Hecht, C. C., Kiely, J. S., Slivka, S. R.: US20036608082 (2003).
131. Ujjainwalla, F., Chu, I., Goulet, M. T., Louridas, B., Wyvratt, M. J., Warner, D.: US20046818658 (2004).
132. Bakshi R.K.B.K. J., Lai, Y., Nargund, R. P., Palucki, B. I., Park M. K., Sebhat, I. K., Ye, Z., Patchett, A. A.: US20046767915 (2004).
133. Ye, Z., Barakat, K. J., Guo, L., Nargund, R. P., Sebhat, I. K.: US2006115628 (2006).
134. Goulet, M.T., Nargund, R. P., Ujjainwalla, F., Walsh, T. F., Warner, D.: US20067012084 (2006).
135. Bennett, NE, Kim JH, Wolfe DP, Sasaki K, Yoshimura N, Goins WF, Huang S, Nelson JB, de Groat WC, Glorioso JC, Chancellor MB. Improvement in erectile dysfunction after neurotrophic factor gene therapy in diabetic rats. J Urol 2005; 173(5): 1820-1824.
136. Poulter MO, Payne KB, Steiner JP. Neuroimmunophilins: a novel drug therapy for the reversal of neurodegenerative disease? Neuroscience 2004; 128(1): 1-6.
137. Sezen SF, Hoke A, Burnett AL, Snyder SH. Immunophilin ligand FK506 is neuroprotective for penile innervation. Nat Med 2001; 7(10): 1073-1074.
138. Marshall VL, Grosset DG. GPI-1485 (Guilford). Curr Opin Investig Drugs 2004; 5(1): 107-112.
139. Burchardt M, Burchardt T, Anastasiadis AG, Buttyan R, de la Taille A, Shabsigh A, Frank J, Shabsigh R. Application of angiogenic factors for therapy of erectile dysfunction: protein and DNA transfer of VEGF 165 into the rat penis. Urology 2005; 66(3): 665-670.
140. Jesmin S, Sakuma I, Salah-Eklin A, Nonomura K, Hattori Y, Kitabatake A, Diminished penile expression of vascular endothelial growth factor and its receptors at the insulin-resistant stage of a type II diabetic rat model: a possible cause for erectile dysfunction in diabetes. J Mol Endocrinol 2003; 31(3): 401-418.
141. Hurt KJ, Musicki B, Palese MA, Crone JK, Becker RE, Moriarity JL, Snyder SH, Burnett AL. Akt-dependent phosphorylation of endothelial nitric-oxide synthase, mediates penile erection. Proc Natl Acad Sci USA 2002; 99(6): 4061-4066.
142. Yamanaka M, Shirai M, Shiina H, Tanaka Y, Enokida H, Tsujimura A, Matsumiya K, Okuyama A, Dahiya R. Vascular endothelial growth factor restores erectile function through inhibition of apoptosis in diabetic rat penile crura. J Urol 2005; 173(1): 318-323.
143. Rogers RS, Graziottin TM, Lin CS, Kan YW, Lue TF. Intracavernosal vascular endothelial growth factor (VEGF) injection and adeno-associated virus-mediated VEGF gene therapy prevent and reverse venogenic erectile dysfunction in rats. Int J Impot Res 2003; 15(1): 26-37.
144. Lee M, Ryu JK, Oh SM, Lee E, Shin HY, Song SU, Kim SW, Suh JK. Water-soluble lipopolymer as a gene carrier to corpus cavernosum. Int J Impot Res 2005; 17(4): 326-334.
145. Henry GD, Byrne R, Hunyh TT, Abraham V, Annex BH, Hagen PO, Donatucci CF. Intracavernosal injections of vascular endothelial growth factor protects endothelial dependent corpora cavernosal smooth muscle relaxation in the hypercholesterolemic rabbit: a preliminary study. Int J Impot Res 2000; 12(6): 334-339.
146. Gholami SS, Rogers R, Chang J, Ho HC, Grazziottin T, Lin CS, Lue TF. The effect of vascular endothelial growth factor and adeno-associated virus mediated brain derived neurotrophic factor on neurogenic and vasculogenic erectile dysfunction induced by hyperlipidemia. J Urol 2003; 169(4): 1577-1581.
147. Byrne RR, Henry GD, Rao DS, Huynh TT, Pippen AM, Annex BH, Hagen PO, Donatucci CF. Vascular endothelial growth factor restores corporeal smooth muscle function in vitro. J Urol 2001; 165(4): 1310-1315.
148. Shabsigh, R.: US20046706682 (2004).
149. Deng W, Bivalacqua TJ, Hellstrom WJ, Kadowitz PJ. Gene and stem cell therapy for erectile dysfunction. Int J Impot Res 2005; 17 Suppl 1: S57-63.
150. Stief CG, Wetterauer U, Schaebsdau FH, Jonas U. Calcitonin-gene-related peptide: a possible role in human penile erection and its therapeutic application in impotent patients. J Urol 1991; 146(4): 1010-1014.
151. Bivalacqua TJ, Champion HC, Abdel-Mageed AB, Kadowitz PJ, Hellstrom WJ. Gene transfer of prepro-calcitonin gene-related peptide restores erectile function in the aged rat. Biol Reprod 2001; 65(5): 1371-1377.
152. Lincoln J, Crowe R, Blacklay PF, Pryor JP, Lumley JS, Burnstock G. Changes in the VIPergic, cholinergic and adrenergic innervation of human penile tissue in diabetic and non-diabetic impotent males. J Urol 1987; 137(5): 1053-1059.
153. Crowe R, Lincoln J, Blacklay PF, Pryor JP, Lumley JS, Burnstock G. Vasoactive intestinal polypeptide-like immunoreactive nerves in diabetic penis. A comparison between streptozotocin-treated rats and man. Diabetes 1983; 32(11): 1075-1077.
154. Shen ZJ, Wang H, Lu YL, Zhou XL, Chan SW, Chen ZD. Gene transfer of vasoactive intestinal polypeptide into the penis improves erectile response in the diabetic rat. BJU Int 2005; 95(6): 890-894.
155. Claudino MA, Priviero FB, Camargo EA, Teixeira CE, De Nucci G, Antunes E, Zanesco A. Protective effect of prior physical conditioning on relaxing response of corpus cavernosum from rats made hypertensive by nitric oxide inhibition. Int J Impot Res 2007; 19(2): 189-195.
156. Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol 2006; 28(7): 451-495.
157. Salem EA, Kendirci M, Hellstrom WJ. Udenafil, a long-acting PDE5 inhibitor for erectile dysfunction. Curr Opin Investig Drugs 2006; 7(7): 661-669.
158. Qiu Y, Bhattacharjee S, Kraft P, Mathew John T, Haynes-Johnson D, Jiang W, Sui Z, Lundeen S. JNJ-10280205 and JNJ-10287069: Novel PDE5 inhibitors as clinical candidates for erectile dysfunction. Int J Impot Res 2006; 18(5): 477-483.
159. Li W, Wayne GS, Lallaman JE, Chang SJ, Wittenberger SJ. An improved synthesis of pyran-3,5-dione: application to the synthesis of ABT-598, a potassium channel opener, via Hantzsch reaction. J Org Chem 2006; 71(4): 1725-1727.
160. Boy KM, Guernon JM, Sit SY, Xie K, Hewawasan P, Boissard CG, Dworetzky SI, Natale J, Gribkoff VK, Lodge N, Starrett JE, Jr. 3-Thioquinolinone maxi-K openers for the treatment of erectile dysfunction. Bioorg Med Chem Lett 2004; 14(20): 5089-5093.
161. Cowart M, Latshaw SP, Bhatia P, et al. Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction. J Med Chem 2004; 47(15): 3853-3864.
162. Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocartin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res 2004; 16(1): 51-59.
163. Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci 2003; 994: 96-102.
164. Kendirci M, Zsengeller Z, Bivalacqua TJ, et al. Poly(Adenosine diphosphate-ribose) polymerase inhibition preserves erectile function in rats after cavernous nerve injury. J Urol 2005; 174(5): 2054-2059.